Maarten A. Huismans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maarten A. Huismans has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Jeanine M. L. Roodhart
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
11 shared publications - Miriam Koopman
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
10 shared publications - Lidwien P. Smabers
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
9 shared publications - Carla S. Verissimo
HUB Organoids B.V., Utrecht, the Netherlands, part of the Life Science Business of Merck KGaA, Darmstadt, Germany
8 shared publications - Edwin Cuppen
Hartwig Medical Foundation, Amsterdam, The Netherlands
8 shared publications - Elske C. Gootjes
Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
8 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (9) , 1554
Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial
- 25 September 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (9) , 1554
Open AccessCorrection: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial
- 7 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (12) , 1744-1753
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial
Background Treatment options for RAS-mutant metastatic colorectal cancer (mCRC) remain limited. Based on preclinical work with patient-derived organoids, we investigated a triple therapy of binimetinib, lapatinib, and vinorelbine in a Phase I/II trial. Methods Forty patients with RAS-mutant mCRC received escalating doses of binimetinib and lapatinib with vinorelbine 17.5 mg/m² in three-weekly schedules. Phase I aimed to determine the Recommended Phase II Regimen (RP2R), while Phase II evaluated Overall Response Rate using Simon’s two-stage design. Pharmacokinetic analyses were performed on cycle 1 day 3. Results The Maximum Tolerated Dose was established at lapatinib 750 mg QD and binimetinib 30 mg BID (both 5 days on/2 days off), with vinorelbine 17.5 mg/m² on days 3 and 10 every 21 days. Toxicities included diarrhoea (75%), rash (65%), and increased CPK (57%). Among 33 evaluable patients, no objective responses occurred, with 9 (27%) achieving stable disease, lasting beyond 3 months (maximum: 297 days) in three patients. Pharmacokinetics showed dose-proportional exposure for binimetinib but not lapatinib. Binimetinib absorption may be affected by colostomy and loperamide-induced constipation. Conclusions The triple combination showed moderate tolerability and termination occurred after the first stage of Phase II due to insufficient efficacy. Our findings highlight challenges in translating organoid-derived drug combinations to clinical practice. Clinical Trial Registration: EudraCT 2019-004987-23
- 7 April 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (12) , 1744-1753
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial
Background Treatment options for RAS-mutant metastatic colorectal cancer (mCRC) remain limited. Based on preclinical work with patient-derived organoids, we investigated a triple therapy of binimetinib, lapatinib, and vinorelbine in a Phase I/II trial. Methods Forty patients with RAS-mutant mCRC received escalating doses of binimetinib and lapatinib with vinorelbine 17.5 mg/m² in three-weekly schedules. Phase I aimed to determine the Recommended Phase II Regimen (RP2R), while Phase II evaluated Overall Response Rate using Simon’s two-stage design. Pharmacokinetic analyses were performed on cycle 1 day 3. Results The Maximum Tolerated Dose was established at lapatinib 750 mg QD and binimetinib 30 mg BID (both 5 days on/2 days off), with vinorelbine 17.5 mg/m² on days 3 and 10 every 21 days. Toxicities included diarrhoea (75%), rash (65%), and increased CPK (57%). Among 33 evaluable patients, no objective responses occurred, with 9 (27%) achieving stable disease, lasting beyond 3 months (maximum: 297 days) in three patients. Pharmacokinetics showed dose-proportional exposure for binimetinib but not lapatinib. Binimetinib absorption may be affected by colostomy and loperamide-induced constipation. Conclusions The triple combination showed moderate tolerability and termination occurred after the first stage of Phase II due to insufficient efficacy. Our findings highlight challenges in translating organoid-derived drug combinations to clinical practice. Clinical Trial Registration: EudraCT 2019-004987-23
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Baseline characteristics of the study population, with key demographic, clinical, and molecular details from regular diagnostic sequencing.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Baseline characteristics of the study population, with key demographic, clinical, and molecular details from regular diagnostic sequencing.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Genomic landscape of 36 tumors and/or PDOs derived from patients with mCRC. Top, microsatellite stability, tumor mutational load, tumor mutational burden, and whether the sequencing was performed on the PDOs or the tumor of origin; bottom, somatic driver mutations. MS, microsatellite status; MSI, microsatellite instability; MSS, microsatellite stability; Seq, sequencing; TML, tumor mutational load.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Genomic landscape of 36 tumors and/or PDOs derived from patients with mCRC. Top, microsatellite stability, tumor mutational load, tumor mutational burden, and whether the sequencing was performed on the PDOs or the tumor of origin; bottom, somatic driver mutations. MS, microsatellite status; MSI, microsatellite instability; MSS, microsatellite stability; Seq, sequencing; TML, tumor mutational load.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Tables S1-S6 and Figures S1–S8
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Tables S1-S6 and Figures S1–S8
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Clinical variables related to PDO establishment success: CEA, LDH, mutational status, sex, primary tumor sidedness, prior chemotherapeutic treatment, metastatic site of the biopsy, WGS success, and aggregated biopsy color (brown, pink, red, and white). CEA, carcinoembryonic antigen; mut, mutant.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Clinical variables related to PDO establishment success: CEA, LDH, mutational status, sex, primary tumor sidedness, prior chemotherapeutic treatment, metastatic site of the biopsy, WGS success, and aggregated biopsy color (brown, pink, red, and white). CEA, carcinoembryonic antigen; mut, mutant.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
A, Heatmap of the drug sensitivity per PDO for different types of systemic treatment. The columns show the normalized GRAUC (left) and AUC (right), respectively. Potential other treatment options for intermediate or high 5-FU and oxaliplatin–resistant PDOs, as well as intermediate or high 5-FU and oxaliplatin–sensitive but 5-FU and irinotecan–resistant PDOs, are shown in black bars. PDOs that were not screened are shown in gray. B, Sensitivity (GRAUC) to doublet and triplet chemotherapy showing increased sensitivity with the addition of irinotecan. C, Sensitivity (normalized GRAUC) to panitumumab for PDOs categorized according to the tumor’s mutational status and primary tumor sidedness (RAS-mutant, BRAF-mutant, and/or right-sided; RAS/BRAF-WT and left-sided. Boxplots show the minimum, median, maximum, upper and lower quartiles, and individual data points. iri, irinotecan; oxa, oxaliplatin; TT, trifluridine/tipiracil.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
A, Heatmap of the drug sensitivity per PDO for different types of systemic treatment. The columns show the normalized GRAUC (left) and AUC (right), respectively. Potential other treatment options for intermediate or high 5-FU and oxaliplatin–resistant PDOs, as well as intermediate or high 5-FU and oxaliplatin–sensitive but 5-FU and irinotecan–resistant PDOs, are shown in black bars. PDOs that were not screened are shown in gray. B, Sensitivity (GRAUC) to doublet and triplet chemotherapy showing increased sensitivity with the addition of irinotecan. C, Sensitivity (normalized GRAUC) to panitumumab for PDOs categorized according to the tumor’s mutational status and primary tumor sidedness (RAS-mutant, BRAF-mutant, and/or right-sided; RAS/BRAF-WT and left-sided. Boxplots show the minimum, median, maximum, upper and lower quartiles, and individual data points. iri, irinotecan; oxa, oxaliplatin; TT, trifluridine/tipiracil.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Correlations between patient response (best RECIST response, size change of all target lesions, and the biopsied lesion) and PDO response (normalized GRAUC per treatment in A–C and AUC in D–F). ROC curves showing the performance of the PDO classification based on GRAUC. The curve plots the true-positive rate (sensitivity) against the false-positive rate (1 − specificity). The AUC indicates the model’s ability to distinguish between responders and nonresponders to 5-FU and oxaliplatin, defined by size change of all target lesions (G) and the biopsied lesion (H). Kaplan–Meier PFS (I) and OS (J) curves of patients stratified by PDO sensitivity to 5-FU and oxaliplatin, based on normalized GRAUC (cutoff = 0.63). Censored events are indicated by vertical bars on the corresponding curve. The table underneath each plot denotes the numbers at risk. Log-rank test–based P value is shown. SN-38, active metabolite of irinotecan.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Correlations between patient response (best RECIST response, size change of all target lesions, and the biopsied lesion) and PDO response (normalized GRAUC per treatment in A–C and AUC in D–F). ROC curves showing the performance of the PDO classification based on GRAUC. The curve plots the true-positive rate (sensitivity) against the false-positive rate (1 − specificity). The AUC indicates the model’s ability to distinguish between responders and nonresponders to 5-FU and oxaliplatin, defined by size change of all target lesions (G) and the biopsied lesion (H). Kaplan–Meier PFS (I) and OS (J) curves of patients stratified by PDO sensitivity to 5-FU and oxaliplatin, based on normalized GRAUC (cutoff = 0.63). Censored events are indicated by vertical bars on the corresponding curve. The table underneath each plot denotes the numbers at risk. Log-rank test–based P value is shown. SN-38, active metabolite of irinotecan.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Schematic overview of the study. Patients underwent a biopsy of a metastasis for PDO culture and WGS, before starting a new line of systemic treatment. Predictors of successful PDO establishment were identified: male sex, increased LDH, biopsy in academic hospitals, optimized culture conditions, and experience. A total of 42 PDOs were screened for standard-of-care treatments, and the patient received standard systemic treatment. PDO response was correlated with patient response, and the association between PDO response and survival was assessed. (Created in BioRender. Roodhart, J. [2025] https://BioRender.com/by1f1uq.)
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Schematic overview of the study. Patients underwent a biopsy of a metastasis for PDO culture and WGS, before starting a new line of systemic treatment. Predictors of successful PDO establishment were identified: male sex, increased LDH, biopsy in academic hospitals, optimized culture conditions, and experience. A total of 42 PDOs were screened for standard-of-care treatments, and the patient received standard systemic treatment. PDO response was correlated with patient response, and the association between PDO response and survival was assessed. (Created in BioRender. Roodhart, J. [2025] https://BioRender.com/by1f1uq.)
- Open Access
- 22 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5015-5026
Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Purpose: Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective studies are needed to confirm their predictive value. Experimental Design: Patients with mCRC underwent a metastatic biopsy for PDO establishment, before starting new systemic treatment. Predictors of PDO establishment were identified. PDOs were incubated with a seven-drug panel, including the patient’s treatment, to determine drug sensitivity as measured by CyQUANT cell viability [area under the nonfitted “curve” of the raw viability or growth rate inhibition values (AUC and GRAUC) and concentration that gives half-maximal viability or GR inhibition (IC50 and GR50)]. Patient response was measured by size change of biopsied and all target lesions. The diagnostic performance was evaluated by positive predictive value, negative predictive value, and area under the ROC curve. Additionally, the association between PDO response and survival was assessed. Results: A total of 232 patients were included, and 205 biopsies were obtained. PDO establishment success increased from 22% to 75%, yielding 52% overall. Male sex, increased lactate dehydrogenase, biopsy in academic hospitals, optimized culture conditions, and experience were related to PDO establishment success. In this interim analysis, focused on oxaliplatin-based doublet chemotherapy, 42 PDOs were screened. PDO drug sensitivity significantly correlated with the response of the biopsied lesion (R = 0.41–0.49, P < 0.011) and all target lesions (R = 0.54–0.60, P < 0.001) for all treatments combined. The 5-fluorouracil and oxaliplatin PDO screens demonstrated high predictive accuracy (positive predictive value: 0.78; negative predictive value: 0.80; area under the ROC curve: 0.78–0.88) and were associated with progression-free survival and overall survival (P = 0.016 and 0.049). Conclusions: We identified predictors for successful mCRC PDO establishment and validated that PDOs can accurately predict patient outcomes during systemic treatment, specifically with 5-fluorouracil and oxaliplatin.
- 22 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5015-5026
Open AccessPatient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Purpose: Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective studies are needed to confirm their predictive value. Experimental Design: Patients with mCRC underwent a metastatic biopsy for PDO establishment, before starting new systemic treatment. Predictors of PDO establishment were identified. PDOs were incubated with a seven-drug panel, including the patient’s treatment, to determine drug sensitivity as measured by CyQUANT cell viability [area under the nonfitted “curve” of the raw viability or growth rate inhibition values (AUC and GRAUC) and concentration that gives half-maximal viability or GR inhibition (IC50 and GR50)]. Patient response was measured by size change of biopsied and all target lesions. The diagnostic performance was evaluated by positive predictive value, negative predictive value, and area under the ROC curve. Additionally, the association between PDO response and survival was assessed. Results: A total of 232 patients were included, and 205 biopsies were obtained. PDO establishment success increased from 22% to 75%, yielding 52% overall. Male sex, increased lactate dehydrogenase, biopsy in academic hospitals, optimized culture conditions, and experience were related to PDO establishment success. In this interim analysis, focused on oxaliplatin-based doublet chemotherapy, 42 PDOs were screened. PDO drug sensitivity significantly correlated with the response of the biopsied lesion (R = 0.41–0.49, P < 0.011) and all target lesions (R = 0.54–0.60, P < 0.001) for all treatments combined. The 5-fluorouracil and oxaliplatin PDO screens demonstrated high predictive accuracy (positive predictive value: 0.78; negative predictive value: 0.80; area under the ROC curve: 0.78–0.88) and were associated with progression-free survival and overall survival (P = 0.016 and 0.049). Conclusions: We identified predictors for successful mCRC PDO establishment and validated that PDOs can accurately predict patient outcomes during systemic treatment, specifically with 5-fluorouracil and oxaliplatin.